The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
Komal Jhaveri, Howard A Burris rd, Timothy A. Yap, Erika Hamilton, Hope S. Rugo, Jonathan W. Goldman, Stephen G. Dann, Feng Liu, Gilbert Y. Wong, Heike I. Krupka, Geoffrey I. Shapiro
Abstract
Although CDK inhibitors may stem the proliferation of cancer cells, resistance remains an issue, and currently there are limited biomarkers to predict response to therapy. Ongoing research investigating CDK inhibitors in cancer is of paramount importance to define appropriate and effective treatment regimens.
Topics & Concepts
Cyclin-dependent kinaseMedicineCell cycleCancer researchKinaseCancerBiologyInternal medicineCell biologyAdvanced Breast Cancer TherapiesCancer-related Molecular PathwaysCancer Genomics and Diagnostics